Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

B1040000

Betamethasone dipropionate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Betamethasone 17,21-dipropionate, 9α-Fluoro-16β-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 17,21-dipropionate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C28H37FO7
CAS Number:
5593-20-4
Molecular Weight:
504.59
MDL number:
MFCD00133140
UNSPSC Code:
41116107
PubChem Substance ID:
329773156
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

betamethasone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

[H][C@@]12C[C@H](C)[C@](OC(=O)CCl)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)C3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

1S/C27H34ClFO7/c1-5-22(33)35-14-21(32)27(36-23(34)13-28)15(2)10-19-18-7-6-16-11-17(30)8-9-24(16,3)26(18,29)20(31)12-25(19,27)4/h8-9,11,15,18-20,31H,5-7,10,12-14H2,1-4H3/t15-,18-,19-,20-,24-,25-,26?,27-/m0/s1

InChI key

UOCNBCVPZWLUKX-HOBFILNXSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Betamethasone dipropionate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Betamethasone 17,21-dipropionate is a glucocorticoid with anti-inflammatory and immunosuppressive activity.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1067001

Betamethasone acetate, United States Pharmacopeia (USP) Reference Standard

1067704

Betamethasone dipropionate, United States Pharmacopeia (USP) Reference Standard

1069007

Betamethasone valerate, United States Pharmacopeia (USP) Reference Standard

1068004

Betamethasone sodium phosphate, United States Pharmacopeia (USP) Reference Standard

B1055000

Betamethasone 21-valerate, European Pharmacopoeia (EP) Reference Standard

B1054000

Betamethasone 17-valerate, European Pharmacopoeia (EP) Reference Standard

B1000000

Betamethasone, European Pharmacopoeia (EP) Reference Standard

B1030000

Betamethasone acetate, European Pharmacopoeia (EP) Reference Standard

B1045000

Betamethasone sodium phosphate, European Pharmacopoeia (EP) Reference Standard

Y0001065

Betamethasone valerate impurity mixture, European Pharmacopoeia (EP) Reference Standard

Y0001027

Betamethasone valerate for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR1398

Betamethasone, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001416

Betamethasone dipropionate for peak identification, European Pharmacopoeia (EP) Reference Standard

1066009

Betamethasone, United States Pharmacopeia (USP) Reference Standard

1069018

Betamethasone Valerate Related Compound A, United States Pharmacopeia (USP) Reference Standard

1067307

Betamethasone benzoate, United States Pharmacopeia (USP) Reference Standard

PHR1779

Betamethasone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1780

Betamethasone Valerate, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001925

Betamethasone dipropionate for system suitability A, European Pharmacopoeia (EP) Reference Standard

BP041

Betamethasone sodium phosphate, British Pharmacopoeia (BP) Reference Standard

BP575

Betamethasone, British Pharmacopoeia (BP) Reference Standard

BP043

Betamethasone 21-valerate, British Pharmacopoeia (BP) Reference Standard

BP042

Betamethasone valerate, British Pharmacopoeia (BP) Reference Standard

1067045

Betamethasone Acetate Related Compound D, United States Pharmacopeia (USP) Reference Standard

1067726

Betamethasone Dipropionate Related Compound B, United States Pharmacopeia (USP) Reference Standard

1067737

Betamethasone Dipropionate Related Compound C, United States Pharmacopeia (USP) Reference Standard

1067760

Betamethasone Dipropionate Related Compound F , United States Pharmacopeia (USP) Reference Standard

1067781

Betamethasone dipropionate Related Compound H, United States Pharmacopeia (USP) Reference Standard

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H360FD,H373

Hazard Classifications

Repr. 1B - STOT RE 2

Target Organs

Liver,Kidney,Endocrine system

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

监管及禁止进口产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Catherine Queille-Roussel et al.
The Journal of dermatological treatment, 24(4), 250-254 (2011-11-23)
The efficacy and safety of calcipotriol plus betamethasone dipropionate ointment in the treatment of psoriasis vulgaris has consistently been demonstrated in several clinical trials. For treatment of scalp psoriasis, more convenient formulations are required. Therefore, new lipophilic alcohol-free gel formulations
Naresh Punwani et al.
Journal of the American Academy of Dermatology, 67(4), 658-664 (2012-01-28)
Janus-associated kinases (JAKs) are involved in signal transduction from a variety of cytokines implicated in the pathogenesis of psoriasis, including interleukin (IL)-12, IL-23, and interferon-γ. INCB018424, a small molecule inhibitor of JAK1 and JAK2, inhibits cytokine-induced JAK/signal transducers and activators
Srinath Reddy et al.
Acta paediatrica (Oslo, Norway : 1992), 101(3), e130-e133 (2011-11-23)
Phimosis is a common paediatric urological disorder and often necessitates circumcision. We prospectively evaluated local steroid therapy (LST) as the first choice therapy for such children. Two hundred and sixty symptomatic boys up to 15 years of age (mean 34
Mohd Hanif Zulfakar et al.
International journal of pharmaceutics, 434(1-2), 399-405 (2012-06-14)
The current work examined the effect of fish oil (FO) and betamethasone dipropionate (BD) on the growth of immortalized HaCaT keratinocytes. HaCaT cells were grown and treated with FO and/or BD, and proliferation determined using the MTT method. The cells
Shivam Kapila et al.
The Australasian journal of dermatology, 53(2), 98-105 (2012-05-11)
Psoriasis (Pso) in children may be confused clinically with atopic dermatitis (AD) and, indeed, the two conditions may co-exist. The aim of this study was to determine historical and clinical features that are different in paediatric Pso and AD and
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service